{"schema_version":"secwatch.filing_event.v1","accession":"0001999371-25-020361","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2025-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.393967+00:00","generated_at":"2026-05-16T13:01:39.012382+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Tonix licenses exclusive worldwide rights to TNX-4900 for neuropathic pain from Rutgers University","bullets":["Licensed exclusive worldwide rights to TNX-4900 (S1R antagonist) from Rutgers University for chronic neuropathic pain.","TNX-4900: Ki=7.5 nM, >100-fold selectivity over Sigma-2, oral bioavailability ~28%.","Preclinical efficacy in diabetic and chemotherapy-induced neuropathic pain models without tolerance or motor impairment.","Company plans IND-enabling studies; no financial terms disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-25-020361","json":"https://secwatch.observer/filing/0001999371-25-020361.json","markdown":"https://secwatch.observer/filing/0001999371-25-020361.md","text":"https://secwatch.observer/filing/0001999371-25-020361.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000199937125020361/0001999371-25-020361-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000199937125020361/tonix-8k_121625.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:01:39.012382+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}